Candel Therapeutics Highlights Promising CAN-2409 Trial Findings

Candel Therapeutics Showcases Groundbreaking Phase 3 Trial Data

NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel) (NASDAQ: CADL), a pioneering biopharmaceutical company dedicated to developing innovative biological immunotherapies for cancer treatment, has made headlines with its recent announcement regarding the presentation of Phase 3 data from its CAN-2409 study. This momentous event is scheduled to take place at the prestigious American Society for Radiation Oncology (ASTRO) Annual Meeting, a gathering of leaders in the field, running from late September to early October.

Details of the CAN-2409 Presentation

The highlight of this year's conference will undoubtedly be the oral presentation led by Glen Gejerman, MD, MBA, from Hackensack University Medical Center. The abstract, titled "Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409 + Prodrug Combined with Standard of Care External Beam Radiation for Newly Diagnosed Localized Prostate Cancer," aims to provide clinicians and researchers with compelling insights into this promising treatment.

Presentation Specifics

• Abstract Overview: Focuses on innovative approaches combining CAN-2409 with current standard therapies for localized prostate cancer.
• Session Title: SS 03 - GU 1: Advances in Localized Prostate Cancer.
• Date & Time: Set for Sunday, September 28, with a focused session from 2:30 PM to 2:40 PM PT.
• Venue: Room 24, Moscone Center, San Francisco.

Significance of the Research

This trial marks a pivotal step not only for Candel but also for patients facing the challenges of localized prostate cancer. As standard treatments continue to evolve, the integration of CAN-2409 into existing protocols could represent a leap forward in enhancing treatment efficacy and patient outcomes.

ASTRO Highlights Session

Moreover, the abstract's inclusion in the ASTRO Science Highlights - Genitourinary Cancer session underscores the significance of the findings. Attendees will gain insights into the latest breakthrough research in genitourinary oncology, scheduled for September 28 at 8:00 AM PT.

Candel Therapeutics: A Leader in Cancer Immunotherapy

Candel Therapeutics takes pride in its focus on creating off-the-shelf, viral immunotherapy products that can trigger personalized immune responses against tumors. The company has developed two leading clinical-stage platforms utilizing novel genetically modified viruses—adenovirus and herpes simplex virus (HSV). CAN-2409 stands out as a flagship candidate from the adenovirus platform.

Previous Trials and Regulatory Milestones

The company recently completed pivotal trials demonstrating CAN-2409's potential to meet vital endpoints in localized prostate cancer treatments. Elsewhere, exciting results were also documented in Phase 2a trials addressing non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

Thanks to its promising results, the FDA has recognized CAN-2409 by granting it the Regenerative Medicine Advanced Therapy Designation for newly diagnosed patients in the aforementioned cancer categories. Earlier, similar designations underscored Candel’s commitment to creating accessible and impactful treatment options in oncology.

Future Prospects for CAN-3110

Looking beyond CAN-2409, Candel’s lead candidate from the HSV platform, CAN-3110, is currently undergoing a promising phase 1b trial targeting recurrent high-grade glioma. Its initial findings have drawn positive attention from the medical community, further establishing Candel as a trailblazer in the search for effective cancer therapies.

Advancements in Viral Immunotherapy

Candel’s innovative enLIGHTEN™ Discovery Platform employs sophisticated analytics to augment its HSV-based therapies. By harnessing insights from human biology, the company aims to push the boundaries of what viral immunotherapies can achieve for patients battling solid tumors.

Investor Insights and Engagement

For investors looking to connect, Candel Therapeutics welcomes inquiries. The Vice President of Investor Relations and Business Development, Theodore Jenkins, is available for discussions. His contact information ensures that dialogues about the company's transformative growth and strategies remain open.

Frequently Asked Questions

What is CAN-2409?

CAN-2409 is Candel Therapeutics' lead product candidate designed to enhance immune responses in patients with localized prostate cancer.

When will the important presentation occur?

The oral presentation will take place on September 28 during the ASTRO meeting, focusing on phase 3 trial results.

Who is leading the presentation?

Dr. Glen Gejerman from Hackensack University Medical Center will present the findings.

What is the significance of the FDA designations?

FDA designations like Fast Track and Regenerative Medicine Advanced Therapy highlight the potential of CAN-2409 to provide significant benefits for patients.

How is Candel contributing to cancer treatment?

Candel is innovating in the area of viral immunotherapies that can elicit personalized immune responses, improving treatment outcomes for different cancer types.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.